NCT05478083View on ClinicalTrials.gov

A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

June 1, 2027

Study Completion Date

October 1, 2027

Conditions
Polycystic Liver DiseaseAutosomal Dominant Polycystic Kidney
Interventions
DRUG

Leuprorelin

Treatment consist of leuprorelin 3.75 mg once monthly for the first 3 months followed by 3-monthly injections of 11.25 mg. The direct start group will use leuprorelin for 36 months. The delayed start group will use standard of care in the first 18 months.

Trial Locations (2)

6525 GA

NOT_YET_RECRUITING

Radboudumc, Nijmegen

9713 GZ

RECRUITING

Groningen universitair medical center, Groningen

All Listed Sponsors
collaborator

Radboud University Medical Center

OTHER

lead

University Medical Center Groningen

OTHER